Obsidian Therapeutics (NASDAQ:OBX) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Obsidian Therapeutics from “sell” to “hold.”
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $39.00 average price target, despite ratings ranging from sell to strong buy.
• OBX opened at $13.98, near the lower end of its 12-month range of $11.52 to $49.97; the company is developing engineered TIL cell therapies for solid tumors.

Obsidian Therapeutics (NASDAQ:OBX - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Sunday, Wall Street Zen reports.

OBX has been the subject of a number of other reports. Piper Sandler assumed coverage on shares of Obsidian Therapeutics in a report on Wednesday, August 5th. They set an "overweight" rating and a $42.00 target price for the company. Weiss Ratings began coverage on Obsidian Therapeutics in a report on Wednesday, September 2nd. They set a "sell (d-)" rating on the stock. TD Cowen started coverage on Obsidian Therapeutics in a research report on Thursday, August 6th. They set a "buy" rating for the company. Zacks Research raised Obsidian Therapeutics to a "hold" rating in a research report on Thursday, August 6th. Finally, Leerink Partners began coverage on Obsidian Therapeutics in a report on Tuesday, September 22nd. They issued an "outperform" rating and a $32.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $39.00.

Obsidian Therapeutics Stock Up 0.3%

OBX stock opened at $13.98 on Friday. The firm's 50-day moving average is $15.74. Obsidian Therapeutics has a twelve month low of $11.52 and a twelve month high of $49.97.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.